Investigators Tackle Resistance, Poor Response in Metastatic Melanoma

Rachel Narozniak, MA
Published: Friday, Jan 31, 2020
Dr. Mario Sznol

Mario Sznol, MD
Immune checkpoint inhibitors (ICIs) combined with the anti–CTLA-4 agent ipilimumab (Yervoy) have dramatically improved survival in metastatic melanoma, but resistance and lack of response remain obstacles to wider efficacy, Mario Sznol, MD, said in a presentation during the 4th Annual International Congress on Immunotherapies in Cancer®. Multiple efforts are under way to understand these issues better and develop improved biomarkers for response, Sznol added.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication